CLINICAL TRIALS PROFILE FOR SORAFENIB TOSYLATE
✉ Email this page to a colleague
All Clinical Trials for sorafenib tosylate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00093457 ↗ | Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2004-07-21 | RATIONALE: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying the effectiveness of sorafenib in treating patients who have metastatic or recurrent prostate cancer that has not responded to previous hormone therapy. |
| NCT00093457 ↗ | Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer | Completed | NCIC Clinical Trials Group | Phase 2 | 2004-07-21 | RATIONALE: Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying the effectiveness of sorafenib in treating patients who have metastatic or recurrent prostate cancer that has not responded to previous hormone therapy. |
| NCT00093613 ↗ | Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma | Completed | National Cancer Institute (NCI) | Phase 1 | 2004-12-01 | This phase I trial is studying the side effects and best dose of sorafenib in treating patients with recurrent or progressive malignant glioma. Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth. |
| NCT00093626 ↗ | Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | Completed | Gynecologic Oncology Group | Phase 2 | 2004-10-01 | Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth. This phase II trial is studying how well sorafenib works in treating patients with persistent or recurrent ovarian epithelial or peritoneal cancer. |
| NCT00093626 ↗ | Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 2004-10-01 | Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth. This phase II trial is studying how well sorafenib works in treating patients with persistent or recurrent ovarian epithelial or peritoneal cancer. |
| NCT00095693 ↗ | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | Terminated | National Cancer Institute (NCI) | Phase 2 | 2004-10-01 | Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for sorafenib tosylate
Condition Name
Clinical Trial Locations for sorafenib tosylate
Trials by Country
Clinical Trial Progress for sorafenib tosylate
Clinical Trial Phase
Clinical Trial Sponsors for sorafenib tosylate
Sponsor Name
